Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
The GLP-1 segment accounts for 14% of total diabetes
care market value in North America
North America GLP-1 market
Slide 69
Key observations for Victoza® in the US market
VictozaⓇ value market share within the GLP-1 segment is
48%
GLP-1 value
in bDKK
VictozaⓇ
exenatide
dulaglutide Share of total
other
diabetes care
•
market
60
14%
•
50
12%
CAGR value¹: 38.8%
10%
40
8%
.
30
6%
20
4%
•
10
2%
0
0%
Nov
2012
Nov
2017
1 CAGR for 5-year period
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 value figures (DKK)
changing
diabetes®
Around 80% of commercial and around 90% of Medicare
Part D lives are covered without restrictions
Around 93% of new patients who start on VictozaⓇ have not
used GLP-1 before
Around 70% of prescriptions are for the higher dose 1.8 mg
Source: QIMS monthly, MAT Nov 2017
novo nordiskView entire presentation